Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › NRIX

Nurix Therapeutics

NRIX Lead: Phase 3 8 Biotech Distilled articles ↓ 31 filings & releases ↓ Cash $720M (Aug 31, 2026) ↓ 8 verdicts ↓
ImmunologyNeurologyOncology Small Molecule

Market cap $1.67B 109.2M shares (10-Q, Sep 30, 2026) × $15.30 close Nov 6, 2026

Most recent annual filing: 2026-01-28

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. GS-6791 Ph1 readout2026GS-6791 Ph1 readout, 2026, notable
  2. bexobrutideg (NX-5948) tablet formulation IND2H 2026bexobrutideg (NX-5948) tablet formulation IND, 2H 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (13 active programs)

Technology platforms

DEL-AI

Fully AI-integrated, DNA-encoded library (DEL)-powered drug discovery engine for targeted protein degradation (TPDs and DACs); disease-agnostic; applied to oncology, inflammation, autoimmunity and other therapeutic areas; leverages 5 billion DEL compounds and machine learning for ligand discovery, degrader design, and optimization.

DAC · Pfizer

Degrader Antibody Conjugate platform combining targeted protein degrader payloads with cell/tissue-selective antibody delivery; designed for oncology and non-oncology; partnered with Pfizer for ADC/DAC development.

DEL-AI · Sanofi

AI-integrated drug discovery platform leveraging E3 ligase expertise to identify targeted protein degraders; focus areas include oncology and autoimmune/inflammatory diseases

Discontinued (6)

Capital (as filed)

Cash
$720M cash and cash equivalents · Aug 31, 2026 (10-Q)
Operating cash flow
$616M quarter May 31, 2026 → Aug 31, 2026, year-to-date difference (10-Q)
As stated in coverage
$1.10B cash, runway 2H 2029 per the update of Nov 3, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on Nurix Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-04-13 Buy core Nurix Therapeutics (NRIX) - Scientific Deep Dive for Bexobrutideg and Pipeline Products Bexobrutideg's catalytic BTK degradation mechanism delivers superior clinical responses in heavily pretreated CLL patients, with a fortress balance sheet and high M&A appeal from validated Big Pharma partnerships.
  2. 2026-06-08 Buy core UPDATE: Nurix Therapeutics (NRIX) - Roche Validates the Molecular Assassin Roche's $700M upfront deal validates the platform and fortifies the balance sheet, while the market's muted reaction creates a setup to accumulate before HSR clears and the Phase 3 initiates.
  3. 2026-06-11 Buy core UPDATE: Nurix Therapeutics (NRIX) - The Earlier-Line Read-Through EHA data showing 92.9% ORR in 2L CLL and a clean n=142 safety database confirms bexobrutideg works earlier in the treatment continuum, compounding the Roche deal thesis and making the autoimmune pivot credible.
  4. 2026-07-09 Buy core UPDATE: Nurix Therapeutics (NRIX) - The Re-Rate Delivered The 45% re-rate has consumed the asymmetric setup; the thesis continues to compound on interim catalysts but new capital at $24.69 is underwriting a Phase 3 binary rather than front-running an unpriced re-rate.
  5. 2026-07-21 Buy core UPDATE: Nurix Therapeutics (NRIX) - HSR Clears, $700M Lands HSR clearance removes the last non-clinical uncertainty on the Roche deal, putting $700M in cash on a 30-day clock and leaving only clinical and commercial execution risks ahead.
  6. 2026-08-05 Buy core UPDATE: Nurix Therapeutics (NRIX) - The Binary Goes Live DAYBreak CLL-306 has dosed its first patient with a superiority design against pirtobrutinib, and the Sanofi STAT6 milestone confirms the partnered platform keeps compounding, but the shares now require underwriting a ~2028 Phase 3 readout rather than a near-term re-rate.
  7. 2026-10-12 Buy core UPDATE: Nurix Therapeutics (NRIX) - The Cluster Bomb Gets Shelved Zelebrudomide's discontinuation narrows the pipeline but makes strategic sense given bexobrutideg's Roche partnership and the $1.06B cash runway extending past the ~2028 CLL-306 readout; the core thesis is unchanged.
  8. 2026-11-04 Buy core UPDATE: Nurix Therapeutics (NRIX) - Sanofi Hands Back the STAT6 Swing Sanofi's Phase 1 termination of the STAT6 degrader wipes out ~$455M in future milestones and weakens the platform narrative, but bexobrutideg's CLL-306 superiority trial and $1.1B cash runway into 2H 2029 remain untouched.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (31)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

14 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)